At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BFRI Biofrontera Inc
Trading 03-05 14:21:55 EST
0.8501
-0.0460
-5.13%
High0.8960Low0.8501Vol19.72K
Open0.8743D1 Closing0.8961Amplitude5.12%
Mkt Cap9.90MTradable Cap7.74MTotal Shares11.65M
T/O17.27KT/O Rate0.22%Tradable Shares9.11M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Biofrontera Inc - Sun Pharma May Appeal Patent Board Decision
THOMSON REUTERS  ·  02-26
Biofrontera Inc - Sun Pharma May Appeal Patent Board Decision
U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 to Be Unpatentable
THOMSON REUTERS  ·  02-26
U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma’s Patent 11,697,028 to Be Unpatentable
PTAB Invalidates Sun Pharma Patent Claims in Biofrontera Dispute
Reuters  ·  02-26
PTAB Invalidates Sun Pharma Patent Claims in Biofrontera Dispute
Biofrontera Locks Phase 1 PK Study Database for Ameluz in Actinic Keratoses Expansion
Reuters  ·  02-17
Biofrontera Locks Phase 1 PK Study Database for Ameluz in Actinic Keratoses Expansion
Biofrontera Inc - Supplemental Nda Submission for Extremities, Neck and Trunk Indication Expected in Q3 2026
THOMSON REUTERS  ·  02-17
Biofrontera Inc - Supplemental Nda Submission for Extremities, Neck and Trunk Indication Expected in Q3 2026
Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities
THOMSON REUTERS  ·  02-17
Biofrontera Inc. Announces Database Lock of Phase 1 Pharmacokinetics Study of Ameluz® for Actinic Keratoses on Trunk and Extremities
Biofrontera Raises 2025 EBITDA Outlook While Keeping Revenue Target
TIPRANKS  ·  02-14
Biofrontera Raises 2025 EBITDA Outlook While Keeping Revenue Target
FDA Accepts Biofrontera sNDA Filing for Ameluz PDT in Superficial Basal Cell Carcinoma
Reuters  ·  02-11
FDA Accepts Biofrontera sNDA Filing for Ameluz PDT in Superficial Basal Cell Carcinoma
Biofrontera Inc - FDA Sets Pdufa Date for September 28, 2026
THOMSON REUTERS  ·  02-11
Biofrontera Inc - FDA Sets Pdufa Date for September 28, 2026
Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® Pdt in Superficial Basal Cell Carcinoma
THOMSON REUTERS  ·  02-11
Biofrontera Announces FDA Filing Acceptance of Supplemental New Drug Application for Ameluz® Pdt in Superficial Basal Cell Carcinoma
BRIEF-Biofrontera Announces Positive Results In Phase 3 Study Of Ameluz® Pdt
Reuters  ·  02-09
BRIEF-Biofrontera Announces Positive Results In Phase 3 Study Of Ameluz® Pdt
Biofrontera Reports Positive Phase 3 Results for Ameluz PDT in Treating Actinic Keratoses Beyond Face and Scalp
Reuters  ·  02-09
Biofrontera Reports Positive Phase 3 Results for Ameluz PDT in Treating Actinic Keratoses Beyond Face and Scalp
Biofrontera Inc - to Submit Snda to FDA in Q3 2026
THOMSON REUTERS  ·  02-09
Biofrontera Inc - to Submit Snda to FDA in Q3 2026
Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® Pdt for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint
THOMSON REUTERS  ·  02-09
Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® Pdt for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint
Biofrontera Inc - Ameluz Pdt Achieves 45.6% Clearance Rate in Phase 3 Study
THOMSON REUTERS  ·  02-09
Biofrontera Inc - Ameluz Pdt Achieves 45.6% Clearance Rate in Phase 3 Study
Biofrontera Inc - Primary Endpoint Achieved With Complete Clearance Rate of Ak Lesions
THOMSON REUTERS  ·  02-09
Biofrontera Inc - Primary Endpoint Achieved With Complete Clearance Rate of Ak Lesions
Biofrontera Inc - Ak Lesion Clearance 73.1% in Fas and 80.3% in PPS
THOMSON REUTERS  ·  02-09
Biofrontera Inc - Ak Lesion Clearance 73.1% in Fas and 80.3% in PPS
There's No Escaping Biofrontera Inc.'s (NASDAQ:BFRI) Muted Revenues Despite A 42% Share Price Rise
Simply Wall St.  ·  01-23
There's No Escaping Biofrontera Inc.'s (NASDAQ:BFRI) Muted Revenues Despite A 42% Share Price Rise
Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues Between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth
THOMSON REUTERS  ·  01-13
Biofrontera Inc. Announces Record Preliminary Fourth Quarter 2025 Revenues Between $17.0 Million and $17.5 Million, Representing Approximately 35% Year-Over-Year Growth
Biofrontera Inc. Projects 2025 Revenue Growth of Up to 13%
Reuters  ·  01-13
Biofrontera Inc. Projects 2025 Revenue Growth of Up to 13%

Introduction

Company Name.
Biofrontera Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Issue price:
--